Available Technology

Isothermal Molecular Diagnostic Devices For Biothreat and Public Health Agent Identification

A large percentage of the 8 million urinary tract infections (UTI’s) that occur each year in the U.S. are caused by E. coli. Increasingly, these bacteria-driven UTI’s are resistant to available antibiotics and lead to severe complications. Some studies have indicated that patients could be contracting UTI’s through consumption of tainted meat and produce http://www.pbs.org/wgbh/frontline/article/can-e-coli-in-supermarket-meat... http://news.ubc.ca/2015/02/04/antibiotic-resistant-e-coli-detected-on-va...). The 2014 WHO release Antimicrobial Resistance: Global Report on Surveillance observed that fluoroquinolones were ineffective in more than half of patients with UTI’s caused by E. coli. Early and specific identification of drug resistant E. coli is thus critical in formulating effective patient treatment plans. Patient treatments can be delayed due to lengthy pathogen identification techniques. Detection of a suspected pathogen is currently performed using urine cultures microscopy, leukocyte esterase and tests. These tests can take 1-2 days to complete and require microbiological lab facilities. Simple (CLIA-waved) molecular diagnostics for bedside testing can significantly reduce time to treatment.
Patent Abstract: 
LLNL researchers are developing a battery-powered molecular diagnostic (MDx) platform for biothreat and public health agent identification. LLNL researchers developed isothermal molecular diagnostic assays to detect and identify DNA from pathogenic bacteria, including E.
applications 
Internal Laboratory Ref #: 
30816
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin